Signaling through Rho GTPase pathway as viable drug target.
about
Targeting Cdc42 in cancerRho kinase as a target for cerebral vascular disordersIdentification of potential small molecule binding pockets on Rho family GTPasesSmall molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility.The role of HTS in drug discovery at the University of Michigan.Targeted gain-of-function screening in Drosophila using GAL4-UAS and random transposon insertions.β-Arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation.Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease.RhoA/Rho-kinase and vascular diseases: what is the link?RhoA inactivation prevents photoreceptor axon retraction in an in vitro model of acute retinal detachment.Development of second-generation small-molecule RhoA inhibitors with enhanced water solubility, tissue potency, and significant in vivo efficacy.Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damagePlanar cell polarity gene expression correlates with tumor cell viability and prognostic outcome in neuroblastomaThe transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin.Phenotypic Screening of Small-Molecule Inhibitors: Implications for Therapeutic Discovery and Drug Target Development in Traumatic Brain Injury.Integrating network, sequence and functional features using machine learning approaches towards identification of novel Alzheimer genesEffects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.Novel p75 neurotrophin receptor ligand stabilizes neuronal calcium, preserves mitochondrial movement and protects against HIV associated neuropathogenesisIn Drosophila, RhoGEF2 cooperates with activated Ras in tumorigenesis through a pathway involving Rho1-Rok-Myosin-II and JNK signallingMicroRNA-223 Attenuates Hypoxia-induced Vascular Remodeling by Targeting RhoB/MLC2 in Pulmonary Arterial Smooth Muscle CellsMetastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.The E. coli CNF1 as a pioneering therapy for the central nervous system diseases.Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 - 2014).Genomic landscape of gastric cancer: molecular classification and potential targets.Emerging roles of RAC1 in treating lung cancer patients.Bioengineered human tumor within a bone niche.SUMOylation of RhoGDIα is required for its repression of cyclin D1 expression and anchorage-independent growth of cancer cellsDiscovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation.Alterations in gene expression profiles correlated with cisplatin cytotoxicity in the glioma U343 cell line.ROCK Inhibition Promotes Attachment, Proliferation, and Wound Closure in Human Embryonic Stem Cell-Derived Retinal Pigmented EpitheliumRho GTPases as therapeutic targets in Alzheimer's disease.Sex steroids and breast cancer metastasis.
P2860
Q27028075-1737B610-70CB-4B1D-8AAD-0FA16B20486CQ28081507-80185AE7-6E60-446C-85F1-F4E22A9282CBQ28481320-A5ACE122-BFB0-4868-B63E-23D587AA639CQ30533280-D8C6A3DE-2499-4D5E-BA90-6E1BAB1B4A3EQ31147980-C7F2828D-516A-4FA9-ACDA-F2CE676C5033Q33488378-51EDD8D6-A6A6-4908-BCA0-7A67523142C3Q33776580-21457A3F-D442-4DE0-9447-438627E6248EQ34366768-AB301967-242C-4E20-A7EB-1C49275168D4Q34378293-1EEE57D9-C783-4769-81D3-B1D1D6C42699Q34646834-CB1955EA-06D1-4EA5-9F6C-6B82143206A8Q35401180-8C0DCF42-9000-46C9-A5C6-765E2FFF5499Q35924101-828B5C82-59C5-4042-85A3-839A27E928DCQ35976974-CD3F1784-FA16-4E89-B5A8-5C1B4F563D86Q36008522-89386551-696F-4232-91AD-79BB1A0808AEQ36125734-94E0E415-A4A7-4B39-9788-EA6D7BA2B3EAQ36166587-24766559-65A4-4741-A637-7F18DED99908Q36206242-00198748-A9B2-4E85-B279-04FE907974BFQ36395644-A79BFD98-89BA-4675-87B4-1EAFACE9DD17Q36790940-C807001B-7D21-4532-91EC-0833972D83D1Q36845623-7D48AD57-437B-4D66-B80E-0FEC40F48417Q38106675-6A633AA1-0111-4ECC-9BBA-CDFA83CBC591Q38176761-EB22C07F-5750-46CC-9BDB-EDC681BEB1B1Q38406085-9B2E1ACF-4409-4E3E-A6D2-C742788E2558Q38837669-7C03EEBE-7FA4-4E65-97E6-50631F7B8D97Q38993407-BE7D031B-B377-4239-81AE-555C0E40DA7CQ39002897-722E4EAB-A05C-4559-ADB4-E60E87240769Q39042922-3C81AA89-221D-4D57-8F4E-133F132118F9Q39206564-07F3A3C6-5F99-4A2F-AAAF-B241DE5578CEQ39595661-C6898DF0-6D8E-4D8F-B332-AC4E70F74D0DQ39757559-BC4CAF92-1806-466F-845D-108D0CD14167Q42360527-C95659F0-2AAE-4A8F-BCA5-3DCD400D7018Q47110501-EC8E660E-9624-447B-90C4-B9AB61447D07Q53292930-4048845F-4BFC-42C6-8326-934AE65A43CA
P2860
Signaling through Rho GTPase pathway as viable drug target.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Signaling through Rho GTPase pathway as viable drug target.
@en
Signaling through Rho GTPase pathway as viable drug target.
@nl
type
label
Signaling through Rho GTPase pathway as viable drug target.
@en
Signaling through Rho GTPase pathway as viable drug target.
@nl
prefLabel
Signaling through Rho GTPase pathway as viable drug target.
@en
Signaling through Rho GTPase pathway as viable drug target.
@nl
P2093
P2860
P1476
Signaling through Rho GTPase pathway as viable drug target.
@en
P2093
Frank M Longo
Huchen Zhou
Stephen M Massa
Yan-Hua Chen
P2860
P304
P356
10.2174/092986709787846569
P577
2009-01-01T00:00:00Z